Chemotherapy for metastatic breast cancer-report of a European expert panel (Q35021322)

5 August 2017

1 reference

title

Chemotherapy for metastatic breast cancer-report of a European expert panel (English)

1 reference

5 August 2017

1 reference

4

Gunter von Minckwitz

0 references

author name string

John Crown

1

1 reference

5 August 2017

Véronique Diéras

2

1 reference

5 August 2017

Manfred Kaufmann

3

1 reference

5 August 2017

Stan Kaye

5

1 reference

5 August 2017

Robert Leonard

6

1 reference

5 August 2017

Michel Marty

7

1 reference

5 August 2017

Jean-Louis Misset

8

1 reference

5 August 2017

Bruno Osterwalder

9

1 reference

5 August 2017

Martine Piccart

10

1 reference

5 August 2017

1 December 2002

1 reference

Lancet Oncology Commission

5 August 2017

1 reference

5 August 2017

3

1 reference

5 August 2017

719-727

1 reference

5 August 2017

12

1 reference

Treatment of breast cancer

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Geriatric oncology: challenges for the new century

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Advanced breast cancer: a randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Radiation therapy-induced cardiac injury

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Infusional 5-fluorouracil can be a pain in the neck: A case for repositioning displaced Hickman lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Upper extremity deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Principles of chronic venous access: recommendations based on the Roswell Park experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Patient preferences for chemotherapy schedules used in the treatment of advanced colorectal cancer--a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

A study of quality of life in cancer patients receiving palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Oral chemotherapy: rationale and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel--a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Mitomycin C and vinorelbine in pretreated breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Advanced breast cancer: a phase II trial with gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

A phase II study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Central nervous system metastasis from breast carcinoma. Autopsy study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

Brain metastases in breast cancer: prognostic factors and management.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900927-0

7 January 2021

10.1016/S1470-2045(02)00927-0

Identifiers

DOI

1 reference

5 August 2017

1 reference